Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29. doi:10.3322/caac.2125425559415
   PubMed Web of Science ®Google Scholar
• Li Y, Li YW, Yang T, et al. Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer. PLoS One. 2013;8:1.
   Web of Science ®Google Scholar
• Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;13(10):1011–1019. doi:10.1016/S1470-2045(12)70344-322954507
   PubMed Web of Science ®Google Scholar
• Crino L, Kim D, Riely GJ, et al. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. J Clin Oncol. 2011;29:15. doi:10.1200/jco.2011.29.15_suppl.7514
   Web of Science ®Google Scholar
• Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. New Engl J Med. 2013;368(25):2385–2394. doi:10.1056/NEJMoa121488623724913
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. New Engl J Med. 2014;371(23):2167–2177. doi:10.1056/NEJMoa140844025470694
   PubMed Web of Science ®Google Scholar
• Mezquita L, Auclin E, Ferrara R, et al. Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol. 2018;4(3):351–357. doi:10.1001/jamaoncol.2017.477129327044
   PubMed Web of Science ®Google Scholar
• Zhu LZ, Li XF, Shen YW, et al. A new prognostic score based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Oncotargets Ther. 2016;9:4879–4886. doi:10.2147/OTT.S107279
   PubMed Web of Science ®Google Scholar
• Inomata M, Hayashi R, Tanaka H, et al. Elevated levels of plasma lactate dehydrogenase is an unfavorable prognostic factor in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer, receiving treatment with gefitinib or erlotinib. Mol Clin Oncol. 2016;4(5):774–778. doi:10.3892/mco.2016.77927123277
   PubMedGoogle Scholar
• Ulas A, Turkoz FP, Silay K, et al. A laboratory prognostic index model for patients with advanced non-small cell lung cancer. PLoS One. 2014;9(12):e114471. doi:10.1371/journal.pone.011447125474743
   PubMed Web of Science ®Google Scholar
• Ramalingam S, Goss G, Rosell R, et al. A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1). Ann Oncol. 2015;26(8):1741–1748. doi:10.1093/annonc/mdv22025997818
   PubMed Web of Science ®Google Scholar
• Inomata M, Hayashi R, Yamamoto A, et al. Plasma neuron-specific enolase level as a prognostic marker in patients with non-small cell lung cancer receiving gefitinib. Mol Clin Oncol. 2015;3(4):802–806. doi:10.3892/mco.2015.56826171184
   PubMedGoogle Scholar
• Heiden MGV, Cantley LC, Thompson CB. Understanding the warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–1033. doi:10.1126/science.116080919460998
   PubMed Web of Science ®Google Scholar
• Gallo M, Sapio L, Spina A, Naviglio D, Calogero A, Naviglio S. Lactic dehydrogenase and cancer: an overview. Front Biosci-Landmrk. 2015;20:1234–1249. doi:10.2741/4368
   PubMed Web of Science ®Google Scholar
• Xie H, Hanai JI, Ren JG, et al. Targeting lactate dehydrogenase-A inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells. Cell Metab. 2014;19(5):795–809. doi:10.1016/j.cmet.2014.03.00324726384
   PubMed Web of Science ®Google Scholar
• Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Brit J Cancer. 2003;89(5):877–885. doi:10.1038/sj.bjc.660120512942121
   PubMed Web of Science ®Google Scholar
• Danner BC, Didilis VN, Wiemeyer S, et al. Long-term survival is linked to serum LDH and partly to tumour LDH-5 in NSCLC. Anticancer Res. 2010;30(4):1347–1351.20530451
   PubMed Web of Science ®Google Scholar
• Sgambato A, Casaluce F, Maione P, Gridelli C. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors. Expert Rev Anticanc. 2018;18(1):71–80. doi:10.1080/14737140.2018.1412260
   PubMed Web of Science ®Google Scholar
• Soussi G, Ben Alaya N, Chaouch N, Racil H. Development and validation of a prognostic index for survival in non-small cell lung cancer: results from a Tunisian cohort study. Cancer Epidemiol. 2018;53:111–118. doi:10.1016/j.canep.2018.01.01829414630
   PubMed Web of Science ®Google Scholar
• O’Connell JP, Kris MG, Gralla RJ, et al. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non small-cell lung-cancer treated with combination chemotherapy. J Clin Oncol. 1986;4(11):1604–1614. doi:10.1200/JCO.1986.4.11.16043021920
   PubMed Web of Science ®Google Scholar
• Kim ST, Lee J, Sun JM, et al. Prognostic model to predict outcomes in non-small cell lung cancer patients with erlotinib as salvage treatment. Oncology-Basel. 2010;79(1–2):78–84. doi:10.1159/000320190
   PubMed Web of Science ®Google Scholar
• Albain KS, Crowley JJ, Leblanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung-cancer – the southwest-oncology-group experience. J Clin Oncol. 1991;9(9):1618–1626. doi:10.1200/JCO.1991.9.9.16181651993
   PubMed Web of Science ®Google Scholar
• Espinosa E, Feliu J, Zamora P, et al. Serum-albumin and other prognostic factors related to response and survival in patients with advanced nonsmall cell lung-cancer. Lung Cancer. 1995;12(1–2):67–76.7600032
   PubMed Web of Science ®Google Scholar
• Hespanhol V, Queiroga H, Magalhaes A, Santos AR, Coelho M, Marques A. Survival predictors in advanced non-small cell lung cancer. Lung Cancer. 1995;13(3):253–267.8719065
   PubMed Web of Science ®Google Scholar
• Liu L, He Y, Ge G, et al. Lactate dehydrogenase and creatine kinase as poor prognostic factors in lung cancer: a retrospective observational study. PLoS One. 2017;12(8):e0182168. doi:10.1371/journal.pone.018216828767733
   PubMed Web of Science ®Google Scholar
• Li B, Li C, Guo M, et al. Predictive value of LDH kinetics in bevacizumab treatment and survival of patients with advanced NSCLC. Onco Targets Ther. 2018;11:6287–6294. doi:10.2147/OTT.S17156630310292
   PubMed Web of Science ®Google Scholar
• Deng T, Zhang J, Meng Y, Zhou Y, Li W. Higher pretreatment lactate dehydrogenase concentration predicts worse overall survival in patients with lung cancer. Medicine (Baltimore). 2018;97(38):e12524. doi:10.1097/MD.000000000001252430235773
   PubMed Web of Science ®Google Scholar
• Taniguchi Y, Tamiya A, Isa SI, et al. Predictive factors for poor progression-free survival in patients with non-small cell lung cancer treated with nivolumab. Anticancer Res. 2017;37(10):5857–5862. doi:10.21873/anticanres.1203028982912
   PubMed Web of Science ®Google Scholar
• Giatromanolaki A, Sivridis E, Arelaki S, Koukourakis MI. Expression of enzymes related to glucose metabolism in non-small cell lung cancer and prognosis. Exp Lung Res. 2017;43(4–5):167–174. doi:10.1080/01902148.2017.132871428644754
   PubMed Web of Science ®Google Scholar
• Vanzandwijk N, Mooi WJ, Rodenhuis S. Prognostic factors in Nsclc – recent experiences. Lung Cancer. 1995;12:S27–S33.7551931
   PubMed Web of Science ®Google Scholar
• Gray AL, Minutolo F, Cardelli JA. A role for lactate dehydrogenase in the c-Met/HGF signaling axis. Cancer Res. 2012;72.
   Web of Science ®Google Scholar
• Sanders HR, Li HR, Bruey JM, et al. Exon scanning by reverse transcriptase-polymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer. Cancer Genet-Ny. 2011;204(1):45–52. doi:10.1016/j.cancergencyto.2010.08.024
   PubMed Web of Science ®Google Scholar
• Li YJ, Ye XF, Liu JF, Zha JP, Pei L. Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors. Neoplasia. 2011;13(1):1–U14. doi:10.1593/neo.10112021245935
   PubMed Web of Science ®Google Scholar
• Chun SG, Choe KS, Iyengar P, Yordy JS, Timmerman RD. Isolated central nervous system progression on Crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation? Cancer Biol Ther. 2012;13(14):1376–1383. doi:10.4161/cbt.2225522986231
   PubMed Web of Science ®Google Scholar
• Costa DB, Kobayashi S, Pandya SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol. 2011;29(15):E443–E445. doi:10.1200/JCO.2010.34.131321422405
   PubMed Web of Science ®Google Scholar
• Costa DB, Shaw AT, Ou SHI, et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol. 2015;33(17):1881–1888. doi:10.1200/JCO.2014.59.053925624436
   PubMed Web of Science ®Google Scholar
• Zhang ZG, Guo HW, Lu YL, Hao W, Han L. Anaplastic lymphoma kinase inhibitors in non-small cell lung cancer patients with brain metastases: a meta-analysis. J Thorac Dis. 2019;11(4):1397–+. doi:10.21037/jtd.2019.03.76
   Web of Science ®Google Scholar
• Soria JC, Tan DSW, Chiari R. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study (vol 389, pg 917, 2017). Lancet. 2017;389(10072):908. doi:10.1016/S0140-6736(17)30123-X
   Web of Science ®Google Scholar
• Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. New Engl J Med. 2017;377(9):829–838. doi:10.1056/NEJMoa170479528586279
   PubMed Web of Science ®Google Scholar
• Gettinger SN, Bazhenova LA, Langer CJ, et al. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol. 2016;17(12):1683–1696. doi:10.1016/S1470-2045(16)30392-827836716
   PubMed Web of Science ®Google Scholar
• Shaw AT, Martini JF, Besse B, et al. Efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC) and ALK kinase domain mutations. Cancer Res. 2018;78:13.
   Web of Science ®Google Scholar